Sandoz Looks Ahead To Biosimilar Opportunities

Sees Upside From Aurobindo Deal Collapse; Canada Growth To Outpace US

Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.

Frame_Sheila
Sheila Frame is Sandoz’ US vice-president for marketing, market access and patient services • Source: Sandoz

After sharing her thoughts on the US biosimilars market as a whole – as the country marks the fifth anniversary of biosimilar competition in the form of Sandoz’ Zarxio (filgrastim-sndz) rival to Neupogen (Also see "Sandoz Sees Revolution In US Biosimilars Market" - Generics Bulletin, 25 September, 2020.) – the company’s US vice-president for marketing, market access and patient services, Sheila Frame, has also reflected on the Novartis subsidiary’s own journey in recent years, as it looks ahead to the opportunities on offer for Sandoz in both US and Canadian biosimilars.

“I think the real highlights have been the success that we’ve had with Zarxio,” Frame told Generics Bulletin in the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

Test1234567

Test

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.